Skip to content

Functional vs organic hypogonadism: Is your low T reversible?

Vladimir Kotlov, MD avatar
Vladimir Kotlov, MD: Founder & CEO at Veedma
Oct 09, 2026 · 14 min read

Listen to this article as a podcast episode

July 23, 2026 · 21:13

Often, yes. Functional hypogonadism, a common pattern in middle-aged and older men, is low testosterone caused by obesity, illness, or medications suppressing an otherwise intact hormonal axis, and it can improve when those causes are treated.[1] [2] Organic hypogonadism reflects structural or irreversible damage to the testes, hypothalamus, or pituitary, so the outlook and treatment are different.[1] The key step is not just confirming low testosterone, but measuring LH and FSH so the condition can be classified correctly.[3]

Find the cause before treating it

Choose a lab panel and get a clinical review with clear next steps.

Order your lab panel

Key takeaways

  • Functional hypogonadism is low testosterone caused by suppressive conditions acting on an otherwise intact HPG axis, while organic hypogonadism reflects structural or irreversible damage to the testes, hypothalamus, or pituitary.[1]
  • Male hypogonadism requires both persistent symptoms and consistently low testosterone. A low number alone is not a diagnosis.[3] [4]
  • LH and FSH must be measured with testosterone. High LH plus low testosterone points to primary hypogonadism, while low or normal LH plus low testosterone points to secondary hypogonadism.[3]
  • A 2013 meta-analysis found that weight loss in men with obesity was associated with higher total and free testosterone, lower estradiol, and higher gonadotropin levels.[2]
  • Testosterone gains from weight loss by diet are modest, about 2.9 nmol/L on average compared with about 8.7 nmol/L after bariatric surgery.[2] Weight regain is also common: five years after structured weight-loss programs, people kept off on average only 17 to 29% of the weight they had lost.[5]
  • Organic primary causes such as Klinefelter syndrome, loss of both testes, and chemotherapy-induced testicular failure are typically permanent and usually treated with long-term testosterone therapy,[3] [6] while men with congenital hypogonadotropic hypogonadism can often have fertility induced with specialized hormone treatment.[7]

What functional and organic hypogonadism mean

Functional hypogonadism is low testosterone caused by suppression of an intact HPG axis, whereas organic hypogonadism is caused by structural or irreversible disease of the testes, hypothalamus, or pituitary.[1] Functional hypogonadism is a diagnosis of exclusion, made only after organic testicular, hypothalamic, and pituitary causes have been considered and ruled out. According to the Endocrine Society guideline, every man found to have androgen deficiency should have further evaluation to identify the cause.[3]

Hypogonadism is a clinical syndrome in which persistent symptoms occur together with biochemical testosterone deficiency. The Endocrine Society guideline recommends making the diagnosis only in men with consistent symptoms and signs and unequivocally, consistently low testosterone, confirmed by repeat morning testing.[3] The 2025 European Association of Urology guideline update likewise describes late-onset hypogonadism as low circulating testosterone combined with specific symptoms.[4] The HPG axis is the brain-to-testis signaling pathway that controls testosterone production.

The most important practical difference between the two is prognosis. Functional hypogonadism has no recognized lesion in the axis and is mainly a consequence of obesity, other chronic illness, or medication exposure, so it is potentially reversible. Organic hypogonadism reflects structural failure in the system and usually does not recover.[1]

According to the Endocrine Society guideline, potentially reversible secondary hypogonadism can occur with severe obesity, systemic illness, or medications that suppress the axis, such as opioids and glucocorticoids.[3] Functional hypogonadism is common in middle-aged and older men, in whom it is usually associated with obesity and other chronic conditions.[1]

FeatureFunctional hypogonadismOrganic hypogonadism
What is wrongAxis is intact but suppressedTestes, hypothalamus, or pituitary are structurally impaired
Common driversObesity, metabolic disease, chronic illness, medications, lifestyle factorsGenetic disease, surgery, irradiation, tumor, loss of both testes, chemotherapy
Typical prognosisPotentially reversible or partly reversibleUsually permanent
Fertility implicationsOften preservable if testosterone therapy is avoidedOften impaired, sometimes severely
Usual first treatment pathCorrect suppressive factors, then stimulate natural production when appropriateDepends on site of failure, often lifelong testosterone therapy for primary disease

If you need a deeper explanation of the diagnostic categories, see Primary vs secondary hypogonadism: Where the problem starts and why it changes everything.

Why functional hypogonadism can be reversible

Functional hypogonadism can be reversible because the testes and the central signaling pathway are suppressed rather than destroyed.[1]

In men with obesity and chronic disease, inflammatory signals from fat tissue and increased conversion of testosterone to estradiol are thought to reduce hypothalamic and pituitary drive. The result is secondary hypogonadism in which LH and FSH are low or inappropriately normal, even though the testes may still be able to respond. Consistent with this, weight loss in obese men lowers estradiol and raises gonadotropin levels.[2]

According to Corona and colleagues’ 2013 meta-analysis of 24 studies in the European Journal of Endocrinology, weight loss from a low-calorie diet or bariatric surgery was associated with increases in both total and free testosterone, and men who lost more weight had larger gains.[2] The rise was greater in younger men, men without diabetes, and men with more severe obesity. Few of the included studies were randomized trials, so the evidence is mostly observational.

The same logic applies when the suppressive driver is not body fat. Changing a suppressive medication, improving glycemic control, and treating other chronic illness are the recommended first steps in functional hypogonadism and can improve testosterone without testosterone therapy when the axis remains intact.[1]

Physical activity belongs in the same plan, mainly because it supports weight loss and weight maintenance. In the meta-analysis, the amount of weight lost was the strongest predictor of how much total testosterone rose.[2] In a separate meta-analysis of US weight-loss programs, people who exercised more kept off more weight.[5]

Medication can also target the suppressed signal directly. Enclomiphene, an oral estrogen receptor blocker, acts at the hypothalamus to increase GnRH and LH output, so the testes raise testosterone production themselves while sperm production and testicular size are generally maintained. Evidence on whether raising testosterone this way improves weight loss or long-term health outcomes is limited.

For a more detailed look at the signaling loop that makes this possible, see How the HPG axis works: The brain testis connection explained.

Why reversibility is often limited in practice

Functional hypogonadism can be reversed in principle, but full and lasting reversal is often difficult in practice.

The first limitation is magnitude. In Corona and colleagues’ meta-analysis, total testosterone rose by about 2.9 nmol/L on average with a low-calorie diet, compared with about 8.7 nmol/L after bariatric surgery.[2] A gain of that size may be enough for a man just below the normal range, but not for a man with marked symptoms, severe central obesity, and clearly suppressed gonadotropins.

The second limitation is durability. A 2001 meta-analysis of 29 long-term US weight-loss studies in the American Journal of Clinical Nutrition found that, five years after a structured program, participants had kept off on average 17% of their initial weight loss after balanced low-calorie diets and 29% after very-low-energy diets.[5] Raising testosterone through weight loss and keeping it raised are separate problems.

This is why functional hypogonadism can become effectively permanent. A man with severe obesity, uncontrolled type 2 diabetes, poor sleep, and ongoing opioid use may still have functional hypogonadism on paper, because the axis is not structurally damaged. If those conditions cannot be meaningfully changed, the low testosterone becomes practically irreversible even though it remains biologically classified as functional. How much aging itself lowers testosterone, separate from obesity and illness, is still uncertain.

For these reasons, lifestyle advice alone is often not enough. Repeat testing shows whether testosterone is actually recovering, and some men need medical treatment alongside continued work on weight, metabolic health, and sleep.

What counts as organic hypogonadism

Organic hypogonadism is caused by structural, genetic, or otherwise irreversible damage in the testes or the hypothalamic-pituitary unit.[1] [6] [7]

Organic primary hypogonadism

Primary hypogonadism means the testes are the main site of failure. The brain sends the signal, but the testes cannot produce enough testosterone.

Classic examples include Klinefelter syndrome, loss of both testes from surgery, trauma, or torsion, and testicular failure after chemotherapy or radiation. These are true gonadal failure states, not reversible suppression.[3] [6] According to a 2013 clinical review by Groth and colleagues in the Journal of Clinical Endocrinology and Metabolism, Klinefelter syndrome is the most common sex chromosome disorder in men, affecting about 1 in 660, yet only about a quarter of cases are diagnosed, typically in the mid-30s.[6]

Clinically, organic primary disease usually shows high LH with low testosterone because the pituitary is trying hard to stimulate the testes. In this setting, Enclomiphene will not fix the underlying problem because there is little or no testicular reserve left to recruit.

Organic secondary hypogonadism

Secondary hypogonadism means the signaling defect starts above the testes, in the hypothalamus or pituitary. The testes may be capable of working, but the command signal is impaired.

Examples include pituitary tumors, pituitary damage after surgery, cranial irradiation, and congenital hypogonadotropic hypogonadism, including Kallmann syndrome.[3] [7] According to the 2015 European Consensus Statement on congenital hypogonadotropic hypogonadism, this rare disorder results from deficient production, secretion, or action of GnRH, more than 25 causal genes have been identified, and about half of affected patients also have a reduced or absent sense of smell, the combination called Kallmann syndrome.[7]

Some organic secondary causes are treatable, but not all are reversible. Prolactin-secreting pituitary tumors may improve with targeted therapy, whereas damage after pituitary surgery or irradiation may be permanent. Fertility is not automatically lost in these men. According to the same consensus statement, fertility can be induced in most men with congenital hypogonadotropic hypogonadism using specialized treatment regimens, and about 10 to 20% show spontaneous recovery of reproductive function, although most need lifelong treatment.[7]

How to tell functional from organic hypogonadism

You cannot distinguish functional from organic hypogonadism without measuring testosterone together with LH and FSH.[3]

Free testosterone is the small fraction of circulating testosterone that is not tightly bound to proteins and is available to tissues. Because high SHBG can hide testosterone deficiency, the Endocrine Society guideline recommends measuring free testosterone by equilibrium dialysis, or estimating it with an accurate formula, when total testosterone is near the lower limit of normal or when a condition alters SHBG.[3] In the European Male Ageing Study, published in the New England Journal of Medicine in 2010, late-onset hypogonadism was best identified by at least three sexual symptoms together with total testosterone below 11 nmol/L (320 ng/dL) and free testosterone below 220 pmol/L (64 pg/mL).[8]

The diagnostic sequence is straightforward.

  1. Confirm persistent symptoms and obtain a morning blood draw between 07:00 and 11:00.
  2. Measure total testosterone, free testosterone, LH, and FSH together.
  3. If testosterone is low and LH is high, primary hypogonadism is likely.
  4. If testosterone is low and LH is low or normal, secondary hypogonadism is likely.
  5. If secondary hypogonadism is present, assess for obesity, metabolic disease, medications, alcohol use, sleep disruption, and other suppressive factors.
  6. If testosterone improves after those factors are treated or removed, the pattern supports functional hypogonadism.
  7. If it does not improve, either an organic cause was missed or the functional state is too entrenched to reverse with lifestyle measures alone.

According to the Endocrine Society guideline, identifying the cause is part of diagnosis, not an optional extra after treatment starts.[3] Prescribing testosterone before checking LH and FSH skips the step that determines which treatment fits.

For the full lab strategy, see The complete low testosterone testing guide: What to order, when to test, and how to read results. If you have already been told your results were “normal” despite symptoms, the next step is often better testing rather than no testing. See Why your testosterone test came back “normal” and why that might be wrong.

How classification changes treatment

Treatment differs because functional and organic hypogonadism do not share the same biology, fertility implications, or likelihood of recovery.[1] [3]

Functional hypogonadism treatment path

In functional hypogonadism, the first emphasis is on treating the cause: weight loss, better control of diabetes and other chronic illness, and review of suppressive medications.[1] Some clinicians add a medication that stimulates the body’s own production, such as Enclomiphene, while those measures take effect. Because it works through the brain’s own signal, it does not suppress sperm production or shrink the testes, which matters for men who may want children.

If the underlying drivers improve enough, testosterone may recover without ongoing treatment, so stimulation therapy in this setting does not have to be permanent.

Testosterone therapy is a poor starting point for a man with functional or secondary hypogonadism who still has testicular reserve and may want children. Exogenous testosterone suppresses gonadotropins and spermatogenesis, and the Endocrine Society guideline recommends against starting it in men planning fertility in the near term.[3]

Organic hypogonadism treatment path

Organic primary hypogonadism generally requires lifelong testosterone therapy because the damaged testes cannot respond adequately to stimulation. Fertility is often severely impaired and may require specialist reproductive care.[3] [6]

Organic secondary hypogonadism is more nuanced. If the testes remain viable, gonadotropin-based therapy can restore testosterone production and induce fertility in many men.[7] For men without an immediate fertility goal whose axis is suppressed rather than structurally damaged, Enclomiphene is an oral alternative that raises LH and testosterone without injections.

Starting testosterone therapy before establishing whether low testosterone is functional can commit a man to long-term replacement and suppress sperm production when the cause might have been treatable.

Myth vs fact

Myth: Any low testosterone is permanent

Fact: Functional hypogonadism is often at least partly reversible because the axis is suppressed, not destroyed.[1] In men with obesity, weight loss is associated with higher total and free testosterone and higher gonadotropin levels.[2]

Myth: LH and FSH are optional if the testosterone number is already low

Fact: LH and FSH are required to classify the disorder. High LH with low testosterone suggests primary hypogonadism, while low or normal LH with low testosterone suggests secondary hypogonadism.[3]

Myth: Weight loss alone usually solves functional hypogonadism

Fact: Lifestyle treatment is essential, but the average testosterone gain with diet is modest, about 2.9 nmol/L in a meta-analysis,[2] and most lost weight tends to be regained within five years.[5] Follow-up testing shows whether it has worked, and some men need additional treatment.

Myth: TRT is the best first treatment for every man with low T

Fact: Testosterone therapy is the standard treatment for organic primary hypogonadism, but it suppresses gonadotropins and sperm production, and the Endocrine Society recommends against starting it in men planning fertility in the near term.[3] In functional hypogonadism, treating the underlying cause comes first.[1]

Bottom line

Low testosterone can often be improved, and sometimes normalized, when the problem is functional hypogonadism driven by obesity, metabolic disease, medications, or other suppressive conditions acting on an intact HPG axis. Organic hypogonadism is different because structural damage to the testes, hypothalamus, or pituitary usually makes it permanent, which is why LH and FSH belong in the first round of testing. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have, interpreted by licensed providers. When appropriate, its providers prescribe Enclomiphene, or the Enclomiphene plus Tadalafil tablet when erection or urinary symptoms are also present. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

References

  1. Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102:1067-1075. PMID: 28359097
  2. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168:829-43. PMID: 23482592
  3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
  4. Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025;88:76-102. PMID: 40340108
  5. Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579-84. PMID: 11684524
  6. Groth KA, Skakkebæk A, Høst C, et al. Clinical review: Klinefelter syndrome–a clinical update. J Clin Endocrinol Metab. 2013;98:20-30. PMID: 23118429
  7. Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism–pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11:547-64. PMID: 26194704
  8. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-35. PMID: 20554979

Start with a lab panel

Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.

Order your lab panel

Prefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD

Vladimir Kotlov, MD: Founder & CEO at Veedma

Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.